Figure 4. Box plot shows the relationship between the normalized expression of TTLL12, MZT2B, CDC16 and UBE2T with metastatic progression. (A and B) mRNA and protein levels of TTLL12, CDC16 and UBE2T in 103 tissue samples with diffuse-type GC from patients M0 and M1. (C and D) mRNA and protein of MZT2B, CDC16 and UBE2T in 110 tissue samples with intestinal-type GC from patients M0 and M1. The boxes are drawn from the 75th to the 25th percentile. The vertical lines above and below the box define the maximum and minimum values and the dots indicate outliers, the horizontal line inside the box representing the median. (E and F) mRNA and protein of TTLL12, MZT2B, CDC16 and UBE2T in patients with diffuse (n = 103) and intestinal (n = 110) GC that were associated with M0 and M1. The lines with the gray gradient represent the connections of points M0 and M1 that vary according to the normalized expression value. The expression levels of these genes were validated by qRT-PCR and western blot in 213 patients. (M) presence of metastasis. Mann – Whitney test was used to compare the relative gene expression levels.